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Asthma and Cluonic Obstructive Disease (COPD) both have a high prevalence
worldwide and many clinical and epidemiology studies have been performed assessing
natural history of the diseases and therapies. However, until recently little research was
undertaken assessing any differences between males and females for either disease. This
thesis was developed to firstly review the existing literature in the area of gender
differences in asthma and COPD and then to undertake epidemiological research in areas
where data was lacking.
Chapter 2 of this thesis is a literature review on the differences between males and
females in the natural history of asthma and COPD. It was written in 2001 and since that
time new (but relatively little) research has been undertaken in the field. New literature
was included as part of the manuscript submissions (chapters 3-8) where appropriate.
The review identified that gender research in obstructive lung disease lags behind other
diseases such as cardio-vascular disease which is more advanced in assessing care and
therapy opportunities for men and women. In obstructive airways disease there was a
good literature on incidence and prevalence throughout the human lifespan, but relatively
scant information with regard to gender differences associated with: childhood smoking
and risk of subsequent disease; in utero smoking exposure and effect on infant lung
development; body mass index as a risk factor; severe asthma and high prevalence in
women; genetic and environmental interactions in the disease process; interventions to
prevent either disease; pharmacological trea.tment and rehabilitation. By definitioq
perimenstrual asthma and related biological mechanisms, and asthma at menopause are
gender related, but have not been extensively studied. It is clear that not all ofthese areas
could be studied during this research period using clinical or database cohorts. Therefore,
research waslimited to areas where epidemiological methods could be best utilised and
where data quality would be adequate. The choice of studies was also driven by evidence
available from existing epidemiological data. For examplg COPD incidence and
prevalence is increasing in women in recent years, in part due to the relative decline in
smoking in males versus an increase in smoking especially in young women. Studies
indicate that women may additionally have a different response to tobacco smoke
compared to men, which may result in an increased risk of disease or decline in lung
functionl-s. This led to the decision to investigate how lung function, symptoms, therapy
and care may differ between men and women with COPD, adjusting for factors such as
smoking history, age, body mass and so forth. Understanding the course of the disease
and treaunent differences will help improve care in the future for COPD patienb, more
and more of whom will be women.
The literature revealed that asthma prevalence also shows a gender bias, and it shows an
increase in women in adulthood. Furlhermore there exists a distinct proportional
difference with severity of disease, severe asthma being far more prevalent in females
than males o. This may be in part related to differences in lung physiology and possible
differences in the inflammatory response but also due to differences in treatment between
the sexes and in response to treatnent. It was therefore decided to utilise the General






































































in treating patients with supposedly mild to moderate asthma and to see how therapy can
impact upon morbidity in both sexes after controlling for age, obesity, smoking habit and
so forth. The fact that male and female asthmatic patients may not be treated similarly led
to the hypothesis that severe asthma may results from not only an underlying difference
in airway inflammation and/or remodelling and genetic risk, but also from differences in
exposure to medication. A large scale clinical cohorl study in severe asthma patients was
included in this research to better understand and describe diflerent severe asthma
phenotypes.
Thrs thesis is therefore divided equally between COPD and asthma. with 3 studies in each
disease outlined below.
Summary'of f indings:
Chapter 3 describes the differences between male and female subjects enrolled in the
Euroscop study with regard to COPD symptom incidence, prevalence and remission. The
study found that after adjusting for covariates such as time, packyears ofsrnoking, age at
visit 3, FEVl%predicted, change in FEV1 per year, body mass index (BMI) and atopy that
women had a greater prevalence of all symptoms apart from sputum i e odds ratio (OR)
forwheeze 1.53(95% CI1.22-  1.92) ;  dyspnea 144(95% CI 1 13-  1.83) ;  cough 1.61(95%
CI 1.29- 2 0l) and for sputum I 06(95% CI 0.84- 1.34). Women also exhibited greater
remission of symptoms. Men on the other hand, showed a much stronger association
between their baseline lung function and symptoms and subsequent change in lung
function and symptoms than did women. For example men showed a significant lower
prevalence of wheezing symptoms in association with a higher level of baseline
FEVl%predrcted, an effect not seen in women, and the difference between men and
women was significant (p<005) [women - Odds Ratio 092(95% CI 0.81-1.0-5) men -
OR 078(95% CI 0.72-085) This significantly different effect was also seen for
dyspnea. This suggests that symptom reporting between the sexes differs which may be
due to sociocultural as well as physiological and psychological differences. As men
exhibit a stÍonger association between lung functron and symptoms thrs rnay mean that
symptoms are a better indrcator of disease status and/or underlying pathophysiology in
men than women. Symptom Íeports in women may be misleading if relied upon to assess
disease status or progression. This indicates that it has to be ensured that oblective
measures of lung function are utilised for both diagnosis and subsequent diseas_e
monitoring rather than placing reliance on symptoms alone as often happens currently'.
This study also found that inhaled corticosteroids (ICS) were successful at reducing the
prevalence of sputum in men only. Previously, the Lung Health Study found that
treatment with triamcinolone was only found to reduce dyspnea" and no other symptom
showed any difference in prevalence between the groups, as was the case in other studies
n'". However, all studies to date were not designed to assess the impact of inhaled steroid
treatment on symptoms. Furthermore, and importantly analyses were always withor.rt
stratification by gender and so any gender effects may have been masked. Issues about
reporting sputum that women appear to have'' may confound our finding that ICS works
successfully in men for reducing sputum. [n other words that we could see no apparent
effect in women may well be due to the fact that women prefer not to discuss sputum or
report it accurately. When men changed their smoking habit by increasing the number of
cigarettes moked, phlegm and wheeze also increased, whilst this was not the case in
women who exhibited no significant change in phlegm prevalence or any other symptom.
In fact women showed little significant association with change in smoking habit, accept
lor wheeze where there was a negative association. as women increase their use of
cigarettes per day wheeze even decreased. The lack of female association with change in
smoking and phlegm may again be due to symptom reporting issues, but it could also be
that women simply do not produce as much sputum as men, or that in comparison to
other symptoms, sputum is not so bothersome and thus under reported. Future research
into symptom reporting and perception and the role of treatment and outcome by gender
are required. The principle findings of this study are that smoking, treatment and lung
function have different associations with symptoms in men with COPD than women with
the disease. This indicates that future clinical and epidemiological studies should stratify
analyses by gender to ensure that potential benefits oftreatment are not obscured and that
outcomes due to smoking exposure can be properly assessed.
ChapÍer 4 uses data from the placebo arm of the Euroscop study and analyses risk
factors for decline in FEVr over three years follow-up. The effect of gender, amongst
other co-variates such as age, BMI, FEV1%VC (dichotomised rnto subjects above and
below the median - women 64 50Á and men 63.30Á respectively), FEV1%FVC
(dichotomised into subjects above and below the median, women 65.5oÁ and men 63.'70/o
respectively), specific IgE, pack years of smoking, age at starting to smoke and change in
the number of cigarettes smoked (10 per year), was evaluated. This study shows that
having symptoms at baseline was only associated with lower baseline lung function in
men but not women Obese men additionally exhibited a reduced decline in lung function
compared to other men, an effect not seen in women. However, women who had more
severe airway obstruction at baseline (FEV1%FVC below the median), showed an
increased decline in lung function over time (32rnl per year), compared to women with
less airway obstruction (above the median). The difference between men who had above
and below the median FEV1%FVC value was only 8ml per year. This study indicates that
women who develop more severe airway obstruction may expect to deteriorate more
rapidly than their milder female counterparts. This could be due to the fact that adult
women have smaller airway size and this might magnify any change in FEVI over time
Additionally one mechanism contributing to the development and progression of COPD
in women, might be the observation that women have altered levels of cytokines such as
interleukin-8 (IL-8) due to cyclical hormone activity.rr Increased.IL-8 influences
neutrophil migration and neutrophil chemotaxis in subjects with COPD '*. IL-8 levels are
parlly controlled by progesterone, IL-8 levels rising as progesterone levels fall. Since
smoking induces an attraction of neutrophils to the airways, higher circulating levels of
IL-8 may enhance the susceptibility to cigarette smoke observed in women rn some
studies2'3. Greater understanding of the role of sex-steroid hormones on cytokine activily
and circulating free radicals from cigarette exposure is required to explain this
observation. Another interesting finding from this study is that an increase in the number
of cigarettes smoked caused a steeper annual decline in FEVr in men (l7mls peryear)
without a significant effect in women. However, the difference between men and women
was not sisnificant when an lnteractron term was tested in the model This findine does
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This finding does
support the observation made in Chapter 3, where smoking appears to have a more
deleterious effect with respect to symptoms in men than in women with COPD. Together
these observations also corroborate the intricate association between luns function and
symptoms in males with COPD especially.
Chapter 5 concludes the studies regarding COPD and takes data from the Confronting
COPD International survey. The survey was performed in the USA, Canada, France,
Italy, Germany, The Netherlands, Spain and the UK in 2000 with 3,265 COPD
participants. The study investigated if men and women were offered the same care for
COPD. After adjusting for age, pack-years, country and severe dyspnea (MRC scores 5
and 4), women were less likely to have had spirometry (OR 0.84, 95o/o C.I.0.72-0.98) but
more likely to get smoking cessation advice (OR 1.57, 1.33-1.86). It is interesting that
given the previous two studies indicating the poor association between women's
symptom reports and lung function that women are less likely than men to be tested. Our
data clearly show that women must be given spirometry if an accurate assessment of
disease severity is to be undertaken. It may be that women receive more smoking advice
because clinicians are aware of literature supporting the fact that women find it harder to
give up smoking and thus encourage and support quit attempts with advice 15'16.
Alternatively men may under report being given this advice.
Despite significantly lower pack-years of smoking women were more likely to report
severe dyspnea than men despite similar reports of cough and less mention of sputum.
There were no differences in the risk of hospitalisation or emergency room visit. This
study indicates that care does differ for men and women for COPD and, supporting the
Euroscop findings, that women report more frequently dyspnea for the same level of
smoking exposure.
Chapter 6 tums the focus of the research to asthma. The study was a prospective
database study performed within the General Practice Research Database in the United
Kingdom. 6420 patients (0-45 years) diagnosed with asthma between 0l/01/1995 and
3lll2/2001 taking>2 scripts for short acting beta-agonist - SABA (SABA only group) or
>3 scripts for inhaled corticosteroids - ICS (ICS group) in the first six months following
diagnosis were included. Factors, including gender, which might be associated with
drug utilisation were assessed. We found that a higher rate of oral steroid use was
significantly associated with being female, using ICS, being an adult, and a smoker.
10.5% of SABA group and l3.4Yo of ICS group used oral steroids. Within the SABA
grotp,3TYo stepped up to ICS, the time to first ICS script being significantly associated
with prior hospitalisation (ItR 2.26, CI1.65-3.10) and atopy (RR 1.47, CI 1.33-1.63).
This study indicates that in some asthmatic patients, under-treatnent can result in lack of
asthma control and result in oral steroids being required to treat exacerbations. Being
female as well as a smoker resulted in greater oral steroid requirement. This indicates that
doctors should therefore advise all patients to quit smoking, but particularly women who
may have gÍeater requirement for oral steroids due to exacerbations. Data from the
Confronting COPD study (see above) are encouraging in that women in that study do
appear to get more frequently anti-smoking advice. However, asthmatics may not get the
same level of advice as COPD patients as the disease is not caused directly by exposure
to cigarette smoke. It is essential that all patients with obstructive lung disease are
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actively encouraged by their clinician to quit smoking and that women in partrcular.are
supported through this process as their quit atterrpts are known to more frequently fail"
Chapter 7 uses data from the same study but we performed a sllrv'ey of the GPs who
treated 400 of the newly diagnosed patients, 200 adults and 200 children, half of whom
were SABA monotherapy users Data was obtained for 255 of the 400 (63.75%). GPs
reviewed patients' notes and provided information regarding symptoms and treatment at
time of first prescription. We were interested to understand how GPs appreciate severity
of asthma in relation to medication prescribed. According to GINA 18, patients with daily
or continuous symptoms which are indicative of persistent, uncontrolled asthma, would
benefit from ICS therapy plus additional therapies such as long acting beta-agonists
(LABAs). However, studies have shown that GPs routinely under estimate severity and
under prescribe steroids, in part due to reliance on symptom presentation rather than
using lung function .easrrrest'tu. Originally the plan had been to assess any gender bias
in prescribing and assessment of asthma severity status in these selected patients but due
to the limited number of questionnaires returned, power became too low to definitively
conclude anything about gender or age impact upon prescribing. Therefore the study
focussed attention on the symptoms presented at time of first treatment, the estimate of
each patient's severity at time of diagnosis by the reviewing physician and the medication
prescribed at time of diagnosis. We found that 460Á of patients who were prescribed
SABA monotherapy had daily or continuous symptoms. Notwithstanding this finding, the
logistic regression model of factors associated with intermittent severity status indicated
that only symptom frequency was associated with this severity 1evel. Those with daily or
continuous symptoms were less likely to be labelled by the reviewing physician as
"intermittent" (OR 0.22 95yo Cl 0. l0-0.49). No other factors (gender, smoking, atopy,
age or symptoms) were associated with obtaining this status. Therefore GPs, despite
knowledge to the contrary, prescribed SABA alone when ICS and/or additional
medication would have benefited the patient. We did find in a sub-analysis that more
females reported daily symptoms than males (36.9% v 32 lYo p:0 a2) and hypothesise
that in a larger population this difference may become significant. SABA monotherapy
was also given more frequently to symptomatic females of all ages than males. lt is
unfortunate that this study was not large enough to be able to expand more on the
observed suggestion that females might be under treated compared to males. We propose
that this should be studied in greater detail in future prospective studies
The final chapter (8) is a repoÍt of a study undertaken in severe asthmatics. The
European Network for Understanding Mechanisms of Severe Asthma (ENFUMOSA)
performed an observational study in 163 subjects with severe asthma (severe group),
comparing them to 158 subjects whose asthma was controlled by low doses of inhaled
corticosteroids (median dose beclamethasone quivalent 666 'p,g - controlled group). The
patients were predominantly female in the severe group (ratio 4 4: l) versus l,ó: I in the
controlled group. Females reported different trigger factors for exacerbations to men
including sinusitis and work exposures. Peri-menstrual worsening of asthma was an
additional risk factor in women. Additionally increased BMI was more predominant in
females than males in the severe group. A number of hypotheses weÍe generatedby thts




neutrophilic inflammation, components of irreversible airway obstruction and had less
frequent atopy. Additionally it was suggested that severe asthma might be characterised
by diminished or sub-optimal sensitivity to glucocorticosteroids. None of these factors
were tested in an interaction with sex and so we cannot therefore infer from this study if
these factors differ for males and females.
FT]TT]RE PERSPECTIVES
The Euroscop COPD sub-analyses have shown that lung function and symptoms are
more closely associated in men than in women This has important ramifications for
clinical care of the patient and for clinical trials. Currently FEVI is the primary outcome
in phase lll trials for registration but agencies such as the FDA increasingly require
evidence of symptom improvement or quality of hfe changes. This is because in milder
patients, increments in FEV1 from baseline can be very small and of little clinical
subsequence to the patient, but symptom improvements such as a reduction in nocturnal
symptoms, can greatly improve the patients' quality of life. However, the subjective
nature of symptom reporting makes validation of such data difficult. We therefore need
to understand how initial lung function and changes in lung function over time are
associated with sympton-r prevalence, remission and incidence in men and women for
both asthma and COPD and alternatively how symptoms may predict or are related to
changes in lung function. Our data suggest hat analyses of clinical trial data particularly
of symptoms, must be stratified by sex, as symptom reporting by women is not related to
improvements in obJective nleasures of lung function. Analysing both genders together
may obscure positive findings of symptom improvements in men. Doctors also need to
understand how symptom presentation at diagnosis may correspond to subsequent
deterioration of lung function and how symptoms may relate to disease status. The
studies have shown us that spirometry is vital if an accurate assessment of drsease
severity is to be established as the current general practice reliance of symptoms alone for
disease assessment would be parlicularly unreliable in female patients. Further research is
needed to understand symptom perception and the underlying mechanisms that may lead
to symptoms, for exampie hyperinflation, under-nourishment, airlvay size, and hormonal
status.
To be able to accurately assess how treatment may improve symptoms, further Íesearch is
required to better understand why symptom reporling differs in men and women.
Previous qualitative research in teenagers indicates that males do not find it socially
acceptable to admit to illness of any kind and attempt to conceal illness from their peers,
as being fit and tough was highly valued and that sickness was considered weak and
incompetent r'). Females on the other hand, had no such social confines to admitting to
illness, and rather sorority supporl was mobilised upon reporting illness This could
explain the greater reports of all syrnptoms by women, but sputum reporting appears to be
affected by a different bias and is of particular relevance in smokers with COPD.
Qualitative interview techniques are required to investigate why women may find it
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